Index S&P 500 P/E - EPS (ttm) -3.18 Insider Own 2.55% Shs Outstand 1.19B Perf Week 2.04%
Market Cap 10.55B Forward P/E 3.70 EPS next Y 2.43 Insider Trans 0.20% Shs Float 1.14B Perf Month 2.28%
Income -3790.10M PEG - EPS next Q 0.55 Inst Own 81.89% Short Float 4.32% Perf Quarter -2.81%
Sales 14.26B P/S 0.74 EPS this Y -16.13% Inst Trans -1.64% Short Ratio 3.17 Perf Half Y -29.49%
Book/sh 13.20 P/B 0.68 EPS next Y 9.30% ROA -8.83% Short Interest 49.41M Perf Year -15.43%
Cash/sh 0.72 P/C 12.40 EPS next 5Y 0.59% ROE -21.25% 52W Range 6.85 - 13.55 Perf YTD -27.79%
Dividend Est. 0.48 (5.32% ) P/FCF 5.54 EPS past 5Y - ROIC -12.63% 52W High -33.65% Beta 0.89
Dividend TTM 0.48 (5.34% ) Quick Ratio 0.86 Sales past 5Y 5.04% Gross Margin 38.88% 52W Low 31.24% ATR (14) 0.27
Dividend Ex-Date May 23, 2025 Current Ratio 1.58 EPS Y/Y TTM -6809.78% Oper. Margin 5.76% RSI (14) 56.74 Volatility 1.42% 2.05%
Employees 32000 Debt/Eq 0.92 Sales Y/Y TTM -6.88% Profit Margin -26.57% Recom 2.73 Target Price 10.83
Option/Short Yes / Yes LT Debt/Eq 0.92 EPS Q/Q -2808.28% Payout - Rel Volume 0.72 Prev Close 8.92
Sales Surprise 0.59% EPS Surprise 1.65% Sales Q/Q -11.28% Earnings May 08 BMO Avg Volume 15.56M Price 8.99
SMA20 2.91% SMA50 7.37% SMA200 -15.50% Trades
Volume 11,169,524 Change 0.78%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-06-25 Initiated Goldman
Neutral
$10
Jul-19-24 Resumed Jefferies
Buy
$15
Oct-23-23 Downgrade BofA Securities
Neutral → Underperform
$13 → $9
Jun-23-23 Downgrade Barclays
Equal Weight → Underweight
$11
Apr-24-23 Downgrade Barclays
Overweight → Equal Weight
$11
Feb-17-23 Downgrade BMO Capital Markets
Outperform → Market Perform
$16 → $14
Jan-27-23 Upgrade Jefferies
Hold → Buy
$13 → $15
Nov-10-22 Upgrade UBS
Sell → Neutral
$9 → $12
Nov-08-22 Upgrade Piper Sandler
Underweight → Neutral
$10
Oct-21-22 Resumed Jefferies
Hold
$11
Jun-14-22 Initiated UBS
Sell
$9
May-10-22 Downgrade Piper Sandler
Neutral → Underweight
$10
Mar-01-22 Downgrade Raymond James
Outperform → Mkt Perform
Mar-01-22 Downgrade BofA Securities
Buy → Neutral
$21 → $13
Jun-15-21 Initiated Citigroup
Neutral
$16
Apr-07-21 Resumed RBC Capital Mkts
Outperform
$24
Mar-08-21 Downgrade Goldman
Buy → Neutral
$20 → $15
Mar-02-21 Downgrade JP Morgan
Overweight → Neutral
$21 → $18
Feb-26-21 Downgrade Wolfe Research
Outperform → Peer Perform
$17
Jan-05-21 Initiated Argus
Hold
Show Previous Ratings
Jun-12-25 04:30PM
Jun-10-25 05:00AM
Jun-09-25 09:29AM
07:22AM
Jun-06-25 02:04PM
11:53AM
Loading…
Jun-03-25 11:53AM
Jun-02-25 08:00AM
May-27-25 06:59AM
May-23-25 05:45AM
May-22-25 06:59AM
May-09-25 12:39PM
03:21AM
02:33AM
(Thomson Reuters StreetEvents)
May-08-25 03:49PM
(Morningstar Research) +5.70%
12:38PM
09:30AM
Loading…
09:30AM
08:15AM
08:03AM
07:10AM
(Associated Press Finance)
06:59AM
06:45AM
06:30AM
May-07-25 12:27PM
08:15AM
06:59AM
May-05-25 04:30PM
09:15AM
12:40AM
May-02-25 01:20PM
10:00AM
10:01AM
Loading…
May-01-25 10:01AM
Apr-30-25 07:42PM
Apr-29-25 09:56AM
Apr-28-25 05:05AM
Apr-27-25 03:06PM
08:20AM
Apr-25-25 09:15AM
06:59AM
Apr-24-25 05:01AM
Apr-23-25 12:22PM
Apr-22-25 07:17AM
(Pharmaceutical Business Review)
Apr-21-25 06:59AM
Apr-14-25 09:06AM
06:59AM
Apr-11-25 09:55AM
Apr-09-25 04:22AM
Apr-08-25 09:56AM
Apr-07-25 09:27AM
06:59AM
Apr-03-25 02:19PM
(Morningstar Research) -5.77%
Apr-01-25 01:04PM
Mar-30-25 07:05PM
08:20AM
Mar-28-25 06:59AM
Mar-25-25 02:48PM
02:12PM
Mar-21-25 01:32PM
Mar-18-25 03:25PM
05:01AM
Mar-17-25 03:26PM
Mar-13-25 05:01AM
Mar-11-25 09:01AM
Mar-09-25 08:32PM
Mar-05-25 04:30PM
04:03AM
Mar-01-25 02:54PM
Feb-28-25 07:30PM
09:40AM
02:28AM
(Thomson Reuters StreetEvents)
02:16AM
Feb-27-25 04:33PM
(Morningstar Research) -15.21%
04:33PM
03:06PM
01:27PM
11:02AM
08:52AM
08:35AM
07:55AM
07:11AM
07:02AM
(Associated Press Finance)
06:45AM
06:30AM
Feb-26-25 12:13PM
12:03PM
(Pharmaceutical Technology)
08:12AM
Feb-24-25 09:16AM
Feb-21-25 04:07AM
Feb-20-25 10:00AM
Feb-19-25 10:45AM
04:01AM
Feb-18-25 04:35AM
Feb-17-25 04:45PM
Feb-14-25 04:01AM
Feb-13-25 04:01AM
Feb-03-25 04:30PM
Jan-22-25 07:02PM
Jan-20-25 09:10PM
Jan-16-25 12:06AM
Jan-15-25 05:02PM
09:40AM
Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. It provides medicines and treatments in various therapeutic areas such as cardiovascular, oncology, dermatology, eye care, gastroenterology, immunology, and women's healthcare. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan, and Hong Kong. The JANZ segment covers operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses operations in developing markets and emerging economies including in Asia, the Middle East, South and Central America, Africa, and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Smith Scott Andrew Chief Executive Officer May 12 '25 Buy 8.94 60,000 536,262 292,807 May 14 06:00 PM Le Goff Corinne Chief Commercial Officer Apr 15 '25 Option Exercise 0.00 41,112 0 60,441 Apr 16 06:00 PM FINNEY ELISHA W Director Mar 04 '25 Option Exercise 0.00 18,977 0 37,832 Mar 05 07:00 PM Le Goff Corinne Chief Commercial Officer Mar 04 '25 Option Exercise 0.00 37,894 0 36,721 Mar 05 07:00 PM Campbell Paul See Remarks Mar 04 '25 Option Exercise 0.00 207,325 0 328,250 Mar 05 07:00 PM Campbell Paul See Remarks Mar 03 '25 Option Exercise 0.00 19,348 0 144,590 Mar 05 07:00 PM Vivaldi Coelho Rogerio Director Mar 04 '25 Option Exercise 0.00 21,691 0 21,691 Mar 05 07:00 PM Smith Scott Andrew Chief Executive Officer Mar 04 '25 Option Exercise 0.00 96,431 0 266,825 Mar 05 07:00 PM Smith Scott Andrew Chief Executive Officer Mar 03 '25 Option Exercise 0.00 146,700 0 221,178 Mar 05 07:00 PM PARRISH MARK W Director Mar 04 '25 Option Exercise 0.00 18,977 0 140,395 Mar 05 07:00 PM Lyons Dillon JoEllen Director Mar 04 '25 Option Exercise 0.00 18,977 0 77,691 Mar 05 07:00 PM KORMAN HARRY Director Mar 04 '25 Option Exercise 0.00 18,977 0 113,937 Mar 05 07:00 PM Groothuis Leo Frans Director Mar 04 '25 Option Exercise 0.00 18,977 0 40,350 Mar 05 07:00 PM HIGGINS MELINA E Director Mar 04 '25 Option Exercise 0.00 18,977 0 121,213 Mar 05 07:00 PM Malik Rajiv Director Mar 04 '25 Option Exercise 0.00 892,603 0 1,407,415 Mar 05 07:00 PM Malik Rajiv Director Mar 03 '25 Option Exercise 0.00 89,430 0 587,599 Mar 05 07:00 PM CORNWELL W DON Director Mar 04 '25 Option Exercise 0.00 18,977 0 80,342 Mar 05 07:00 PM KILTS JAMES M Director Mar 04 '25 Option Exercise 0.00 18,977 0 136,422 Mar 05 07:00 PM MARK RICHARD A Director Mar 04 '25 Option Exercise 0.00 18,977 0 91,310 Mar 05 07:00 PM Roman Brian Chief Legal Officer Mar 04 '25 Option Exercise 0.00 206,263 0 265,061 Mar 05 07:00 PM Roman Brian Chief Legal Officer Mar 03 '25 Option Exercise 0.00 18,345 0 84,494 Mar 05 07:00 PM Mistras Theodora Chief Financial Officer Mar 04 '25 Option Exercise 0.00 32,472 0 41,815 Mar 05 07:00 PM Mistras Theodora Chief Financial Officer Jan 01 '25 Option Exercise 0.00 24,065 0 23,084 Jan 03 06:00 PM Campbell Paul See Remarks Nov 11 '24 Sale 12.88 26,925 346,686 126,901 Nov 12 07:00 PM Campbell Paul Officer Nov 11 '24 Proposed Sale 12.88 26,925 346,686 Nov 12 04:30 PM Malik Rajiv Director Sep 12 '24 Sale 11.66 139,681 1,628,164 505,838 Sep 13 06:00 PM Malik Rajiv Director Sep 12 '24 Sale 11.71 60,319 706,553 0 Sep 13 06:00 PM Malik Rajiv Director Aug 30 '24 Sale 12.00 50,000 600,000 60,319 Aug 30 06:16 PM Malik Rajiv Director Aug 28 '24 Sale 11.90 50,000 595,075 110,319 Aug 30 06:16 PM Malik Rajiv Director Aug 21 '24 Sale 11.75 100,000 1,175,260 360,319 Aug 23 06:05 PM Malik Rajiv Director Aug 23 '24 Sale 11.75 100,000 1,175,100 160,319 Aug 23 06:05 PM Malik Rajiv Director Aug 22 '24 Sale 11.73 100,000 1,172,630 260,319 Aug 23 06:05 PM Malik Rajiv Director Aug 20 '24 Proposed Sale 11.80 600,000 7,080,000 Aug 20 12:07 PM
